by Sue Robbins | Mar 2, 2020 | Migraine
It’s a quirk of human nature that we touch our eyes, noses and mouths all day long. It’s also a major way we pick up infections like coronavirus. Want to improve your chance of staying healthy? Stop touching your face! One of the more difficult challenges in public...
by Sue Robbins | Mar 2, 2020 | Migraine
In the book “Migraine: A History” (Johns Hopkins University Press), medical historian Katherine Foxhall writes of a disabling disease that has been documented going back thousands of years, though the causes of this neurological disorder are still unclear....
by Sue Robbins | Feb 28, 2020 | Migraine
NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved Nurtec ODT (rimegepant) for the acute treatment of migraine in adults. Nurtec...
by Sue Robbins | Feb 27, 2020 | Migraine
Patients with psoriasis are at increased risk for migraines, according to a research letter published in the Journal of the American Academy of Dermatology. Researchers from the New York University School of Medicine examined data obtained from the 2003-2004 National...
by Sue Robbins | Feb 25, 2020 | Migraine
The United States Food and Drug Administration (US FDA) has just approved Vyepti™ for the preventive treatment of migraine. Vyepti (eptinezumab-jjmr) will be the first intravenous (IV) preventive treatment on the market for migraine disease. It will be available...
by Sue Robbins | Feb 23, 2020 | Migraine
Researchers determined that migraineurs exhibit unique responses to tactile stimuli compared with controls, according to a study published in Cephalalgia. Many migraineurs experience habituation deficits and sensory abnormalities as migraine symptoms, including...
